{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

A survey To undestAnd the dRuG utilization pattErn of Ticagrelor in patients with Non-ST-Segment Elevation Myocardial Infarction (TARGET-NSTEMI)

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

General Questions
  1. How many ACS Patients do you treat in a month? *

  2. Out of your 100 ACS patients, what percentage of patients fall under each of the below categories? *
    3. Type of ACS patient % Patient (Total should be 100%)
    %
    %
    %
  3. How many patients with NSTEMI do you come across in a month? *

  4. What is age distribution of your NSTEMI patients? *
    5. Age categories % Patient (Total should be 100%)
    %
    %
    %
  5. Which cardiac biomarker is elevated in both STEMI and NSTEMI? (Multiple answers can be ticked) *

  6. What are the 3 most common risk factors/ comorbidities you see in your NSTEMI patients? *
    		7.
  7. Do you use risk assessment tools when managing NSTEMI Patients? *

  8. What are the key initial management steps for a patient presenting with NSTEMI, and how do these steps differ from those for STEMI?" *
  9. For high-risk patients (e.g., GRACE >140), what is your preferred initial treatment/management approach? *

  10. Based on your clinical experience, which medications do you most commonly initiate as part of the primary treatment regimen for patients presenting with acute coronary syndrome (ACS)? (Multiple answers can be ticked) *

  11. Do you switch to Single antiplatelet (SAPT) from Dual antiplatelet therapy (DAPT) in NSTEMI patients? *

  12. What percentage of your NSTEMI patients receive single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT)? *
    13. Type of Therapy % Patient
    %
    %
  13. What are your preferred antiplatelet agents in managing NSTEMI patients? *
    14. SAPT DAPT

  14. In your practice currently, what % of NSTEMI patients are on the following anti platelet agents? *
    15. Drug % Patient (Total Should be 100%)
    %
    %
    %
  15. What is your preferred duration for dual antiplatelet therapy (DAPT) with ticagrelor and aspirin in NSTEMI patients? *

  16. What percentage of your NSTEMI patients continue antiplatelet therapy beyond 12 months? *
    17. Antiplatelet drug % Patient
    %
    %
    %
  17. Post PCI which antiplatelet you prefer in patient with high bleeding risk? *

  18. What is your most preferred antiplatelet agent for single antiplatelet therapy (SAPT) in NSTEMI patients? *

  19. In your experience, which dual antiplatelet therapy (DAPT) regimen has shown the best outcomes in NSTEMI patients? *

  20. How long do you prescribe dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor and aspirin for NSTEMI patients? *

  21. What factors influence your decision to prescribe Ticagrelor instead of Clopidogrel for NSTEMI patients? *
  22. Are you aware that Ticagrelor is Available in 60 mg? *

  23. Do you use Ticagrelor 60 mg in NSTEMI patients? *

  24. If yes, what are the specific factors you consider while prescribing 60 mg ticagrelor in NSTEMI?
  25. If No, Why don’t you prefer ticagrelor 60 mg in NSTEMI patients?
  26. In what % of NSTEMI patients you switch from Ticagrelor to Clopidogrel? *

  27. If Yes, After how many month of treatment initiation, do you switch patients from Ticagrelor to Clopidogrel?

  28. When selecting a brand of Ticagrelor for NSTEMI patients, which parameters do you consider most important, such as efficacy, safety profile, cost, patient adherence? *
  29. In your experience, what percentage of NSTEMI Patients discontinue ticagrelor prematurely due to side effect and cost? *

  30. What support do you feel is needed to improve adherence to ticagrelor therapy in your NSTEMI patients? *

  31. If others, please specify
  32. Are you aware of any ongoing clinical trials investigating novel molecules or therapies for NSTEMI? If yes, please describe them in one or two sentences: *
  33. What steps can be taken from patient point of view for the awareness and education about benefits and risks of antiplatelet agents in NSTEMI patients? *
  34. How do you integrate ACC/AHA guidelines into clinical decision-making for NSTEMI patients, and what modifications might be necessary in these guidelines as they evolve with new clinical evidence? *
  35. How do you manage the common adverse effect of shortness of breath in patients taking Ticagrelor, and can you provide examples from your experience where patients had to deal with this or other side effects? *
  36. In your clinical experience, how frequently do patients with NSTEMI develop complications such as heart failure, arrhythmias, stroke, or recurrent cardiovascular events? Could you also share any strategies you find effective in mitigating these risks? *
  37. What are the most common barriers you face in delivering optimal care to NSTEMI patients? *